See more : Serabi Gold plc (SRB.L) Income Statement Analysis – Financial Results
Complete financial analysis of 180 Life Sciences Corp. (ATNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 180 Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- C2C Gold Corp. (CTCGF) Income Statement Analysis – Financial Results
- Mt. Carmel Public Utility Co. (MCPB) Income Statement Analysis – Financial Results
- Fiducial Office Solutions (SACI.PA) Income Statement Analysis – Financial Results
- National General Industries Limited (NATGENI.BO) Income Statement Analysis – Financial Results
- Lizhi Inc. (LIZI) Income Statement Analysis – Financial Results
180 Life Sciences Corp. (ATNF)
About 180 Life Sciences Corp.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 0.00 | 0.00 |
| Gross Profit | -105.68K | -109.00K | -116.30K | -125.33K | -72.24K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.78M | 2.43M | 3.95M | 2.29M | 2.04M | 1.07M | 0.00 |
| General & Administrative | 10.69M | 15.47M | 11.69M | 3.32M | 5.89M | 7.67M | 343.88K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 38.83K | 12.96M | 0.00 | 0.00 |
| SG&A | 10.69M | 15.47M | 11.69M | 3.36M | 18.85M | 7.67M | 343.88K |
| Other Expenses | 0.00 | 246.34B | 770.60K | 264.74K | 250.40K | 0.00 | 0.00 |
| Operating Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Cost & Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Interest Income | 0.00 | 26.67K | 186.21K | 1.09M | 181.41K | 12.24K | 663.02K |
| Interest Expense | 44.83 | 26.67K | 186.21K | 1.09M | 185.14K | 0.00 | 0.00 |
| Depreciation & Amortization | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 23.08K | 52.52K |
| EBITDA | -22.13M | -17.79M | -20.05M | -5.52M | -20.79M | -8.72M | -343.88K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.48M | -17.90M | -15.64M | -5.65M | -20.86M | -8.74M | -343.88K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.81M | -21.77M | -4.71M | -5.26M | -4.54M | -5.75M | 663.02K |
| Income Before Tax | -22.28M | -39.67M | -20.35M | -10.90M | -25.40M | -14.50M | 319.13K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.35M | 942.75K | 23.20K | 20.43K | 9.50K | -1.00 | 195.37K |
| Net Income | -19.94M | -38.73M | -20.32M | -12.01M | -25.39M | -14.50M | 123.76K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -52.60 | -387.26 | -247.86 | -255.46 | -875.66 | -1.45K | 12.38 |
| EPS Diluted | -52.59 | -387.18 | -246.32 | -251.32 | -874.45 | -1.45K | 12.38 |
| Weighted Avg Shares Out | 379.00K | 100.00K | 82.00K | 47.00K | 29.00K | 10.00K | 10.00K |
| Weighted Avg Shares Out (Dil) | 379.09K | 100.02K | 82.51K | 47.77K | 29.04K | 10.00K | 10.00K |
180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
7 Reddit Penny Stocks Seeing the Most Chatter Today
180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC
World’s Largest Food Companies Urged to Step up Efforts on Global Nutrition Crisis
Online Launch of the 2016 Access to Nutrition Index Thursday 14th January 2016 09:00 EST /14:00 GMT/ 15:00 CET via WebEx
Source: https://incomestatements.info
Category: Stock Reports